Path Therapeutics incorporated
$3M Brain Canada Grant awarded to develop MitoREAD
Platform patent filed for MitoREAD
Grants awarded from Dravet Canada and Hotchkiss Brain Institute to pursue drug discovery
First publication of MitoREAD as a drug screening platform in the journal Brain (Impact Factor > 14)
US$300K pre-seed investment received from AJ Therapeutics to further validate novel druggable targets identified by MitoREAD
US$2M seed funding received from Viva BioInnovator to launch drug discovery programs against novel druggable targets
Methods patent filed for PDE4 in epilepsy
Presentation of MitoREAD at Sweet Pharma Day (Montreal, QC)
Relaunched as Stream Neurosciences to advance drug discovery in epilepsy and cognition
Poster presented at AES 2024 summarizing preclinical efficacy of PDE4B allosteric inhibition on seizure activity and cognition
